Skip to content

InfuSystem Holdings INFU Amortization expense related to capitalized debt issuance costs

Amortization expense related to capitalized debt issuance costs at other companies

Viemed Healthcare, Inc. logo
Viemed Healthcare, Inc.VMD
ICU Medical logo
ICU MedicalICUI
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
Phreesia logo
PhreesiaPHR
AdaptHealth logo
AdaptHealthAHCO

Other financials

Income statement

See full
Revenue$33.7M-3.0%
Gross profit$19.7M+2.7%
Operating income$1.6M+157%
Net income$1.0M+481%
EPS (diluted)$0.05+600%

Balance sheet

See full
Cash & equivalents$2.1M+39.8%
Total debt$24.1M-30.4%
Total equity$58.7M+6.5%
Total assets$98.7M-5.4%

Cash flow

See full
Operating cash flow$970.0K-45.5%
CapEx$157.0K+19.8%
Free cash flow$813.0K-50.7%

Valuation

See full
Market cap$205.05M+51.3%
Enterprise value$227.04M+36.2%
P/E25.9×-0.8×
P/S1.4×+0.5×

Profitability

See full
Gross margin56.7%+3.6pp
Operating margin9.1%+3.0pp
Net margin5.6%+3.2pp
FCF margin16.2%+1.0pp

Returns & leverage

See full
Return on equity13.9%+8.0pp
Debt / equity0.4×-0.2×
Current ratio2.1×-0.1×

Where this comes from

Reported directly by InfuSystem Holdings in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: InfuSystem Holdings’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about InfuSystem Holdings's amortization expense related to capitalized debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is InfuSystem Holdings's amortization expense related to capitalized debt issuance costs?
InfuSystem Holdings (INFU) reported amortization expense related to capitalized debt issuance costs of $21K in Q1 2026.
How has InfuSystem Holdings's amortization expense related to capitalized debt issuance costs changed year-over-year?
InfuSystem Holdings's amortization expense related to capitalized debt issuance costs increased by 10.5% year-over-year, from $19K to $21K.
What is the long-term trend for InfuSystem Holdings's amortization expense related to capitalized debt issuance costs?
Over 4 years (2021 to 2025), InfuSystem Holdings's amortization expense related to capitalized debt issuance costs has grown at a -14.4% compound annual growth rate (CAGR), from $151K to $81K.